We found that doubling the sample size led to important cancer pathways being identified more stably and regularly in both the single-platform and cross-platform settings, including pathways related to ERB2, NFKB immune infiltration, and RAF in BRCA, and KRAS, MYC, and PRC2-related pathways in GBM. This evidence concerns the gene MYC and glioblastoma.